Friday, May 09, 2008 4:22:53 PM
Friday May 9, 11:40 am ET
Amylin Pharmaceuticals spent $198,000 lobbying the federal government in first quarter
WASHINGTON (AP) -- Amylin Pharmaceuticals Inc. spent $198,000 lobbying the federal government on prescription drug issues in the first quarter of 2008.
The San Diego, Calif.-based company lobbied on legislation affecting the Medicare prescription drug benefit for seniors and a bill that would require drug companies to disclose gifts given to doctors to help promote pharmaceuticals.
Amylin also lobbied Congress on a bill aimed at updating the U.S. patent system. High-tech companies support the bill that passed the House last year, saying it would cut down on frivolous patent-infringement lawsuits. But the pharmaceutical industry has argued it will weaken patent protections on drugs by reducing infringement penalties. The bill has stalled in the Senate.
The company disclosed its lobbying expenses in a form filed online on April 16 by the Senate's public records office.
Under a federal law enacted in 1995, lobbyists are required to disclose activities that could influence members of the executive and legislative branches. Lobbyists are required to disclose how much they spent in the first six months of the year.
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM